张海 副教授，副主任药师
硕士招生类型：学术型
硕士招生专业：药学
博士招生类型：学术型
博士招生专业：基础医学
所在院系：附属第一妇婴保健院
联系方式：邮箱：zhxdks2005@126.com 手机号码：**
课题组链接：
研究方向
主要任职
科研业绩

药效成分筛选与作用靶点的确证；药物相互作用研究 Screening and identification of effective components of Chinese Medicinal Herbs; Drug-drug interactions
中国妇幼保健协会药事管理专业委员会副主任委员；上海市药理学会药物临床试验专委会委员；《世界临床药物》杂志编委 The deputy director of the pharmacy administration, Specialized Committee, Chinese maternal and child health care association; The committee member of the pharmaceutical clinical trial of Shanghai Pharmacological Society
从事基于药物代谢酶、转运体和靶蛋白的药物相互作用、中药药效成分筛选与作用靶点验证等研究工作，主持国家自然科学基金3项，上海市科委基金3项；获得专利和软件著作权4项；以第一或通讯作者发表SCI论文40余篇。
The research focused on drug-drug interactions based on metabolic enzymes, transporters and target proteins, screening of the efficacy components of Chinese medicinal herbs and verification of the active targets. The research projects completed or under study as PI are as follows: 3 projects of National Natural Science Foundation of China, 3 projects of Shanghai Science and Technology Commission Foundation. The researcher have obtained 4 patents or software copyright, and published more than 40 SCI papers as first author or corresponding author.
第一负责人基金：
1.附子中单酯型生物碱类成分靶向RAAS系统中ACE2-Ang(1-7)-Mas轴抗心衰作用机制研究，**，2020.1-2023.12，国家自然科学基金；55万，第1；
2.五味子乙素结合CB2受体抗肝纤维化作用的分子机制研究，**，2018.1-2021.12，国家自然科学基金；63.5万，第1；
3.中药五味子木脂素类成分抗肝损伤、抗肝纤维化作用评价与机理研究，**，2014.1-2016.12，国家自然科学基金；23万，第1；
4.基于网络药理学和药物代谢动力学的“参附汤”配伍机制研究，2018.6.1-2021.5.30，18ZR**，上海市自然科学基金，20万，第1；
5.基于Hsp90-Cdc37蛋白交互作用的雷公藤红素结构修饰物抗胰腺癌作用评价与作用机理研究, , 2012.10-2014.9, 上海市科委“科技创新行动计划”国际合作项目；30万，第1；
6.养心氏片的二次创新开发，15DZ**，2015.5-2018.4，上海市科委“科技创新行动计划”生物医药领域产学研医合作项目；110万，第1。
近三年发表论文：
1.Coupling Metal-Organic Framework Nanosphere and Nanobody for Boosted Photoelectrochemical Immunoassay of Human Epididymis Protein 4, Anal Chim Acta, 2020, 1107: 145-154. (Co-corresponding author, IF: 5.977)；
2.Cabazitaxel-loaded Bovine Serum Albumin Nanoparticles Perform Superior Anti-prostatic Cancer Effects with Low Toxicity and Magnetic Resonance Imaging Tracer in Rats, International Journal of Nanomedicine, 2020.(Corresponding author，IF:5.115 )；
3.Eliminating Radiation Resistance of Non-small Cell Lung Cancer by Dihydroartemisinin through Abrogating Immunity Escaping and Promoting Radiation Sensitivity by inhibiting PD-L1 expression, Frontier in Oncology, 2020. (First Author, IF: 4.848)；
4.MicroRNA-216a-3p promotes sorafenib sensitivity in hepatocellular carcinoma by downregulating MAPK14 expression, Aging-US, 2020. (Corresponding author，IF: 4.831)；
5.Identification of a novel BACE1 inhibitor, timosaponin A-III, for treatment of Alzheimer’s disease by a cell extraction and chemogenomics target knowledgebase-guided method, Phytomedicine, 2020,75:153244. (Corresponding author, IF:4.268)；
6.Transcriptomic analyses reveal the molecular mechanisms of schisandrin B alleviates CCl(4)-induced liver fibrosis in rats by RNA-sequencing. Chem Biol Interact. 2019 Aug 25;309:108675. (First Author, IF:3.723)；
7.Integrating molecular characterization and metabolites profile revealed CtCHI1’ s significant role in Carthamus tinctorius L, BMC Plant Biology, 2019,19(1): 376-388. (Co-corresponding author, IF:3.497)；
8.Asiatic acid ameliorates CCl4-induced liver fibrosis in rats: involvement of Nrf2/ARE, NF-κB/IκBα and JAK1/STAT3 signaling pathways, Drug Design, Development and Therapy, 2018:12 3595–3605. (Corresponding author, IF:3.208)
9.Asiatic acid attenuates CCl4-induced liver fibrosis in rats by regulating the PI3K/AKT/mTOR and Bcl-2/Bax signaling pathways. International Immunopharmacology, 2018;60, 1-8. (Corresponding author, IF:3.118)；
10.Metabolic profiles revealed anti-ischemia-reperfusion injury of Yangxinshi tablet in Rats, Journal of Ethnopharmacology, 2018, 214:124-133. (First Author, IF:3.115)